67 related articles for article (PubMed ID: 26267707)
1. PGWD: Integrating Personal Genome for Warfarin Dosing.
Pan Y; Cheng R; Li Z; Zhao Y; He J
Interdiscip Sci; 2016 Mar; 8(1):23-7. PubMed ID: 26267707
[TBL] [Abstract][Full Text] [Related]
2. PGWD: integrating personal genome for warfarin dosing.
Pan Y; Cheng R; Li Z; Zhao Y; He J
Interdiscip Sci; 2015 Feb; ():. PubMed ID: 25663116
[TBL] [Abstract][Full Text] [Related]
3. Warfarin pharmacogenomics.
Cavallari LH; Limdi NA
Curr Opin Mol Ther; 2009 Jun; 11(3):243-51. PubMed ID: 19479657
[TBL] [Abstract][Full Text] [Related]
4. Failure of pharmacogenetic-based dosing algorithms to identify older patients requiring low daily doses of warfarin.
Schwartz JB; Kane L; Moore K; Wu AH
J Am Med Dir Assoc; 2011 Nov; 12(9):633-8. PubMed ID: 21450231
[TBL] [Abstract][Full Text] [Related]
5. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
[TBL] [Abstract][Full Text] [Related]
6. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
[TBL] [Abstract][Full Text] [Related]
7. New allele-specific real-time PCR system for warfarin dose genotyping equipped with an automatic interpretative function that allows rapid, accurate, and user-friendly reporting in clinical laboratories.
Kim S; Lee HW; Lee W; Um TH; Cho CR; Chun S; Min WK
Thromb Res; 2012 Jul; 130(1):104-9. PubMed ID: 21911247
[TBL] [Abstract][Full Text] [Related]
8. Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing.
Roper N; Storer B; Bona R; Fang M
J Mol Diagn; 2010 May; 12(3):283-91. PubMed ID: 20228265
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
[TBL] [Abstract][Full Text] [Related]
10. SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement.
Huang SW; Li Q; Zhu SY; Li L; Xiong F; Jia YK; Xu XM
Clin Chem Lab Med; 2009; 47(1):26-31. PubMed ID: 19117406
[TBL] [Abstract][Full Text] [Related]
11. Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes.
Ciccacci C; Rufini S; Politi C; Novelli G; Forte V; Borgiani P
Thromb Res; 2015 Aug; 136(2):367-70. PubMed ID: 26113018
[TBL] [Abstract][Full Text] [Related]
12. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.
King CR; Porche-Sorbet RM; Gage BF; Ridker PM; Renaud Y; Phillips MS; Eby C
Am J Clin Pathol; 2008 Jun; 129(6):876-83. PubMed ID: 18480003
[TBL] [Abstract][Full Text] [Related]
13. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes.
Wen MS; Lee M; Chen JJ; Chuang HP; Lu LS; Chen CH; Lee TH; Kuo CT; Sun FM; Chang YJ; Kuan PL; Chen YF; Charng MJ; Ray CY; Wu JY; Chen YT
Clin Pharmacol Ther; 2008 Jul; 84(1):83-9. PubMed ID: 18183038
[TBL] [Abstract][Full Text] [Related]
15. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
[TBL] [Abstract][Full Text] [Related]
16. Role of warfarin pharmacogenetic testing in clinical practice.
Tan GM; Wu E; Lam YY; Yan BP
Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients.
Perini JA; Struchiner CJ; Silva-Assunção E; Santana IS; Rangel F; Ojopi EB; Dias-Neto E; Suarez-Kurtz G
Clin Pharmacol Ther; 2008 Dec; 84(6):722-8. PubMed ID: 18754001
[TBL] [Abstract][Full Text] [Related]
18. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives.
Yin T; Miyata T
Thromb Res; 2007; 120(1):1-10. PubMed ID: 17161452
[TBL] [Abstract][Full Text] [Related]
19. [Warfarin resistance and related pharmacogenetic information].
Takahashi H
Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
[TBL] [Abstract][Full Text] [Related]
20. Comparative performance of warfarin pharmacogenetic algorithms in Chinese patients.
Liu Y; Yang J; Xu Q; Xu B; Gao L; Zhang Y; Zhang Y; Wang H; Lu C; Zhao Y; Yin T
Thromb Res; 2012 Sep; 130(3):435-40. PubMed ID: 22374335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
